Pr. Thierry Lebret, Head of Urology and Kidney Transplantation Department at Foch Hospital and recently appointed President of the French Urology Association, commented: "Our team is enthusiastic about the acquisition of Focal One HIFU as it responds to a growing demand for more non-invasive prostate cancer treatments. This innovative system adds to our portfolio of solutions offered to prostate cancer patients. Focal One combines state-of-the-art IRM and real-time ultrasound imaging capabilities with targeted HIFU technology to allow precise ablation of prostatic tissue, with reduced side effects."
Pierre Reboul, EDAP TMS France Business Unit Director, added: "We are very pleased with this Focal One acquisition by the prominent Foch Hospital under the leadership of Pr. Lebret. This investment confirms the growing adoption of HIFU for the management of prostate cancer in France as demonstrated during the recent French Urology Association Congress held in Paris last November. Our HIFU Club, organized during this event, gathered more than 50 French Focal One users who shared their experience and appetite for the technology's capabilities. We look forward to continued expansion of HIFU access to more prestigious centers in France."